Top Markets
#1 Pleasing Gold Pleasing Gold +1,499.28%
#2 PulseChain PulseChain +58.12%
#3 Ontology Gas Ontology Gas +37.24%
#4 Merlin's Seal BTC Merlin's Seal BTC +33.75%
#5 ConstitutionDAO ConstitutionDAO +29.14%
#6 BOOK OF MEME BOOK OF MEME +29.14%
#7 Collect on Fanable Collect on Fanable +24.03%
#8 Neiro Neiro +22.56%
#9 Unit Pump Unit Pump +22.12%
#10 Pump.fun Pump.fun +22.12%
Coin of the day
Pleasing Gold Pleasing Gold
Settings
Language
ENGLISH
Currency
USD
Theme
Serina Therapeutics, Inc. Serina Therapeutics, Inc.

Serina Therapeutics, Inc.

SER
Rank in Stocks #26470
Serina Therapeutics, Inc., a biotechnology firm, focuses on creating... Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy. Beyond these, Serina Therapeutics leverages its POZ technology in producing ribonucleic acid (RNA) vaccines delivered via lipid nanoparticles for combating infectious diseases. This company was established in 2006 and is headquartered in Huntsville, Alabama.
Share Price
$2.70
Market Cap
$40.42M
Change (1 day)
-1.28%
Change (1 year)
-48.17%
Country
US
Trade Serina Therapeutics, Inc. (SER)

Category

Healthcare
P/E ratio for Serina Therapeutics, Inc. (SER)
P/E ratio as of 2026 TTM: 0
According to Serina Therapeutics, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Serina Therapeutics, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.